Key Highlights
- USD 1.01 billion is the market capitalization in published market data for Iambic Therapeutics (NASDAQ:IAM), at USD 21.39, up 13.11%. It ties to 47,400,796 shares outstanding (own arithmetic) and sits 33.7% above the USD 16.00 IPO price set on October 14, 2026.
- USD 188.12 million is the market value of SITE Centers (NYSE:SITC) at USD 3.59, up 19.10% on a relative volume of 0.57. Cash after the July dividend was USD 3.55 per share (own arithmetic), and no company-specific catalyst was identified in the filings reviewed.
- USD 135.94 million is the market value of RF Acquisition Corp II (NASDAQ:RFAI), at USD 34.00 on 10,330 shares. The trust held USD 11.14 per public share after August 2026 redemptions, so the quote is 3.05 times trust value (own arithmetic).
- USD 63.99 million is the market value of Exascale Labs (NASDAQ:XLAB), at USD 1.90, up 39.65%. A second data set shows USD 124 million on 91.2 million shares at the October 15 close of USD 1.36, so capitalization depends on the share basis used.
Iambic Therapeutics (NASDAQ:IAM)
Iambic is the largest by a wide margin, and its size is the most recently tested by the market. It priced a USD 150.0 million IPO on October 14, 2026 at USD 16.00, the midpoint of a USD 15 to 17 range, selling 9,375,000 shares with an option for 1,406,250 more, per the prospectus. Trading opened at USD 19.31 and reached USD 22.00. With 47,400,796 shares outstanding, USD 21.39 implies USD 1.01 billion (own arithmetic). Iambic Therapeutics (NASDAQ:IAM) held USD 207.9 million of cash at June 30, 2026 and lost USD 50.1 million in the first half. Gross proceeds plus June cash total USD 357.9 million, so the market value is 2.83 times cash (own arithmetic). The lead program, IAM1363, is an oral HER2 inhibitor in a Phase 1/1b trial, so the valuation rests on early clinical data and an AI-enabled design platform. Nvidia is a backer, and AbbVie and Takeda are partners. The risks are trial setbacks, the 30-day underwriter option, lock-up expirations and large annual losses. A 13.11% move to USD 21.39 implies a USD 18.91 reference price (own arithmetic), which does not tie to the offer, so the session is not confirmed.
SITE Centers (NYSE:SITC)
SITE Centers is a real-estate wind-down, so its market value of USD 188.12 million is best compared with cash, not earnings. Unrestricted cash was USD 238.9 million at June 30, 2026, and the USD 1.00 per share dividend of USD 52.7 million paid July 31 leaves USD 186.2 million (own arithmetic). Divided by 52.475 million shares, that is USD 3.55 per share against the USD 3.59 quote, a 1.1% premium. This is not a liquidation value: wind-down costs, litigation and obligations will reduce payouts. SITE Centers (NYSE:SITC) holds 20% of the DTP joint venture, where a buy-sell had a latest closing date of October 15, 2026, with the partner able to buy that stake for USD 32.4 million or sell its 80% for USD 129.6 million. No outcome was reported in the filings reviewed. Second quarter revenue was USD 6.95 million, down 78%. Published EPS of USD 2.40 and a price to earnings ratio of 1.50 reflect earlier property sale gains. Volume was 866,670 shares, and no catalyst was identified.
RF Acquisition Corp II (NASDAQ:RFAI)
RF Acquisition Corp II is a special purpose acquisition company, so its USD 135.94 million value is a quote on a shell, not an operating business. The figure equals 3,998,108 public shares at USD 34.00 (own arithmetic), which suggests founder shares are excluded. Trust assets fell from USD 122.87 million on September 30, 2025 to USD 44.52 million after August 12, 2026 redemptions, down 63.8% (own arithmetic). Shareholders approved extensions to as late as February 15, 2027 and a merger with Singapore-based Nanyang Biologics, reported at USD 1.5 billion and not independently confirmed. A Form 425 shows 3,956,323 shares, 98.95% of public shares, subject to preliminary redemption requests that can be withdrawn. RF Acquisition Corp II (NASDAQ:RFAI) would then have 41,785 public shares (own arithmetic), a thin float. At USD 34.00 the quote is 3.05 times the USD 11.14 trust value per share, so it is not a reliable valuation. The 10-Q for the quarter ended June 30, 2026 flags going concern doubt and a material weakness in controls.
Exascale Labs (NASDAQ:XLAB)
Exascale Labs is the smallest here in published market data, though its capitalization is the least settled. One data set shows USD 63.99 million, while another shows 91.2 million shares and USD 124 million at the October 15 close, which is 8.4 times fiscal 2026 revenue of USD 14.82 million (own arithmetic). An 8-K signed October 15, 2026 disclosed a USD 8.208 million agreement to supply 12 NVIDIA HGX B300 servers with 96 GPUs to Sunon Inc., equal to 55% of that revenue. Delivery depends on a 30% down payment, chip manufacturer approval and export authorizations. Exascale Labs (NASDAQ:XLAB) listed through a SPAC merger on August 27, 2026, and its 52-week range runs from USD 0.778 to USD 11.170. The net loss was USD 12.16 million, warrants at USD 11.50 remain outstanding, and financing for a USD 71.4 million compute purchase commitment is not disclosed. The company cites a USD 300 million customer pipeline, which it described as prospective opportunities, not backlog.
Where Things Stand
Iambic Therapeutics (NASDAQ:IAM) has the largest market value, USD 1.01 billion, and is backed by a fresh priced offering and USD 207.9 million of cash. Ranked by market value: Iambic USD 1,013.9 million, SITE Centers USD 188.12 million (18.6% of Iambic), RF Acquisition Corp II USD 135.94 million (13.4%) and Exascale Labs USD 63.99 million (6.3%), own arithmetic on published figures. Ranked by premium to a hard anchor, RF Acquisition Corp II leads at 3.05 times trust, then Iambic at 2.83 times cash and SITE Centers at 1.01 times cash. Size is not support. The next catalysts are analyst initiations on Iambic, a joint venture filing from SITE Centers (NYSE:SITC), SPAC redemption steps and the Sunon purchase order.






Please wait processing your request...